Nanni Pidikiti, MD
Cardiovascular Disease · Corinth, MSNPI 1417970518
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,817 of the $13,415 with a category attached, or 65.7%. 32 manufacturers reported payments, led by Boston Scientific at 37.0% of the total. 2025 is the largest year on record at $5,318, more than ten times the $434 reported in 2019.
Across 265 payments — averaging $50.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Penumbra, Inc.$4K
- AstraZeneca$852
- Abiomed$784
- Medtronic$688
- Novo Nordisk$392
- plus $2K from 26 others
What the payments were for
- Travel & lodging$4,59234%
- Food & beverage$8,81766%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 53 | $4,965 |
| Penumbra, Inc. | 23 | $3,726 |
| AstraZeneca | 37 | $852 |
| Abiomed | 27 | $784 |
| Medtronic(2 entities) | 31 | $688 |
| Novo Nordisk | 7 | $392 |
| Pfizer | 23 | $262 |
| Surmodics, Inc. | 2 | $233 |
| Novartis | 14 | $186 |
| Johnson & Johnson | 4 | $184 |
| Amgen | 4 | $168 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $144 |
| Cvrx, Inc. | 1 | $132 |
| United Therapeutics Corporation | 2 | $132 |
| Avinger Inc. | 2 | $105 |
| Chiesi USA, Inc. | 4 | $85 |
| Merck | 4 | $60 |
| Veryan Medical Incorporated | 1 | $49 |
| Cardiva Medical, Inc. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $27 |
| Abbott | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Cook Medical LLC | 3 | $18 |
| Intact Vascular, Inc. | 1 | $16 |
| Daxor Corporation | 1 | $15 |
| Biotronik Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| GE HealthCare | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$3,239
- Farapulse$2,835
- GENERAL - THERAPIES$948
- Impella$388
- BRILINTA$227
- Pounce Thrombectomy$195
- Pounce Venous Thrombectomy System$195
- Pounce Thrombectomy System$195
- Pounce LP Thrombectomy$195
- Rotablator Rotational Atherectomy System Console Kit$149
- Penumbra System$146
- XARELTO$143
- Barostim Neo System$132
- SYMPLICITY G3$124
- Repatha$121
- Wegovy$111
How this compares
$13,415 in reported general payments places this provider in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 104 | $65,164 |
| BrilintaTicagrelor | 53 | $23,276 |
| FarxigaDapagliflozin Propanediol | 18 | $21,311 |
| EntrestoSacubitril/Valsartan | 36 | $15,616 |
| Metoprolol Succinate | 623 | $5,644 |
| Ranolazine ErRanolazine | 106 | $4,470 |
| Montelukast Sodium | 711 | $4,283 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 279 | $2,797 |
| Pantoprazole Sodium | 314 | $2,715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,236 |
| Potassium Chloride | 209 | $1,822 |
| ClopidogrelClopidogrel Bisulfate | 289 | $1,711 |
| Amiodarone Hcl | 165 | $1,696 |
| Prasugrel Hcl | 35 | $1,223 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $65,164104 claims |
| AstraZenecaBrilinta, Farxiga | $852 | $44,58771 claims |
| NovartisEntresto | $186 | $15,61636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Corinth
- Mandar JagtapCorinth$20K
- Kerry MorganCorinth$9K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.